CoChat

Pittsburgh compound B and the postmortem diagnosis of alzheimer disease

Open access
Niedowicz, Dana M., Beckett, Tina L., Matveev, Sergey, Weidner, Adam M., Baig, Irfan, Kryscio, Richard J., Mendiondo, Marta S., LeVine, Harry, Keller, Jeffrey N., Murphy, M.Paul · 2012 · Annals of Neurology
Cited by 38

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objective: Deposition of the amyloid‐β (Aβ) peptide in neuritic plaques is a requirement for the diagnosis of Alzheimer disease (AD). Although the continued development of in vivo imaging agents such as Pittsburgh compound B (PiB) is promising, the diagnosis of AD is still challenging. This can be partially attributed to our lack of a detailed understanding of the interrelationship between the various pools and species of Aβ and other common indices of AD pathology. We hypothesized that recent advances in our ability to accurately measure Aβ postmortem (for example, using PiB), could form the basis of a simple means to deliver an accurate AD diagnosis. Methods: We conducted a comprehensive analysis of the amount of Aβ40 and Aβ42 in increasingly insoluble fractions, oligomeric Aβ, and fibrillar Aβ (as defined by PiB binding), as well as plaques (diffuse and neuritic), and neurofibrillary tangles in autopsy specimens from age‐matched, cognitively normal controls (n = 23) and AD (n = 22) cases, across multiple brain regions. Results: Both PiB binding and the amount of sodium dodecyl sulfate (SDS)‐soluble Aβ were able to predict disease status; however, SDS‐soluble Aβ was a better measure. Oligomeric Aβ was not a predictor of disease status. PiB binding was strongly related to plaque count, although diffuse plaques were a stronger correlate than neuritic plaques. Interpretation: Although postmortem PiB binding was somewhat useful in distinguishing AD from control cases, SDS‐soluble Aβ measured by standard immunoassay was substantially better. These findings have important implications for the development of imaging‐based biomarkers of AD. ANN NEUROL 2012;72:564–570

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.23633

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 16 references

Cited by

See all 38

Metadata

Authors
Niedowicz, D. M., Beckett, T. L., Matveev, S., Weidner, A. M., Baig, I., Kryscio, R. J., Mendiondo, M. S., LeVine, H., Keller, J. N., & Murphy, M. P.
Venue
Annals of Neurology
Publisher
Wiley
Published
2012-10
Volume
72
Issue
4
Pages
564-570
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1985467097
Cited by
38
References
16
FWCI
3.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pittsburgh compound B and the postmortem diagnosis of alzheimer disease. https://app.cochat.ai/papers/10.1002/ana.23633
The paper
Niedowicz, D. M., Beckett, T. L., Matveev, S., Weidner, A. M., Baig, I., Kryscio, R. J., Mendiondo, M. S., LeVine, H., Keller, J. N., & Murphy, M. P. (2012). Pittsburgh compound B and the postmortem diagnosis of alzheimer disease. Annals of Neurology. https://doi.org/10.1002/ana.23633

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.